Prelude Therapeutics’ lead asset won’t be making it to the second act. The precision oncology outfit is pausing development of SMARCA2 degrader PRT3789, leaving just one clinical program left humming ...
Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite selectivity over close homolog, SMARCA4. Rapid, deep and ...
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- October 10, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat ...
WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision oncology company, today announced the first interim clinical data from its ...
To better understand the relationship between SMARCA2 and SMARCA4 in the context of small cell carcinoma of the ovary, hypercalcemic type, we evaluated SMARCA2 expression in 10 small cell carcinoma of ...
Kymera Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to probable global transcription activator SNF2L2 (SMARCA2; ...
Foghorn’s selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- October 10, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback